In a 28-year-old G2P1 woman at 30 weeks + 2 days gestation with intact membranes, stable vital signs, reassuring fetal heart tracing, and anticipated preterm delivery within the next 24–48 hours, what is the most appropriate management of antenatal dexamethasone and magnesium sulfate?

Administer Both Antenatal Corticosteroids AND Magnesium Sulfate for Fetal Neuroprotection

This patient at 30+2 weeks' gestation with anticipated delivery within 24-48 hours should receive BOTH betamethasone (2 doses of 12 mg IM, 24 hours apart) for fetal lung maturity AND intravenous magnesium sulfate (4 g IV loading dose followed by 1 g/hour maintenance) for fetal neuroprotection.

Rationale for Antenatal Corticosteroids

At 30+2 weeks' gestation, this patient falls squarely within the established gestational age range where corticosteroids provide substantial benefit. The evidence is unequivocal: antenatal corticosteroids administered between 24 0/7 and 33 6/7 weeks reduce respiratory distress syndrome, intraventricular hemorrhage, neonatal death, and sepsis 1.

The standard regimen is betamethasone 12 mg intramuscularly, repeated in 24 hours 2. This provides maximum benefit when delivery occurs between 24 hours and 7 days after the first dose, though benefit persists even if delivery occurs sooner.

Key Points on Corticosteroid Administration:

• Timing is critical: Ideally administered when delivery is anticipated within 7 days
• Single course only: Do not repeat unless delivery has not occurred and patient remains at risk after 14 days, AND gestational age remains <34 weeks 1
• Intact membranes are not a contraindication: This patient's intact membranes do not preclude treatment
• No contraindications present: The patient has no diabetes mellitus (which would increase neonatal hypoglycemia risk with late preterm steroids) 2

Rationale for Magnesium Sulfate

At 30+2 weeks' gestation with imminent delivery, this patient meets clear criteria for magnesium sulfate administration for fetal neuroprotection. The evidence demonstrates that magnesium sulfate reduces cerebral palsy (RR 0.71) and moderate-to-severe cerebral palsy (RR 0.60) when administered before 32 weeks' gestation 3.

The recommended protocol is a 4 g IV loading dose over 20 minutes, followed by 1 g/hour maintenance infusion until delivery (maximum 12 hours or 50 g cumulative dose) 4, 5.

Key Points on Magnesium Sulfate Administration:

• Gestational age window: Strongest evidence supports use before 30 weeks, but guidelines recommend administration through 29+6 weeks at minimum 4. Given this patient is at 30+2 weeks, she falls just outside the strictest cutoff but within the range where many guidelines suggest consideration up to 32-34 weeks 4, 3
• Timing requirement: Must anticipate delivery within 24 hours 4
• Route matters: IV administration is preferred over IM for more predictable serum levels 5
• Duration limits: Do not continue beyond 12 hours or exceed 50 g total dose 5. The FDA warning about prolonged use (>5-7 days) does not apply to this short-term neuroprotective indication 6

Important Clinical Caveats

Monitoring During Magnesium Sulfate Administration:

• Assess patellar reflexes regularly (loss indicates toxicity)
• Monitor respiratory rate (should remain >12/minute)
• Ensure adequate urine output (magnesium is renally excreted)
• Have calcium gluconate available as antidote for toxicity 7

Common Pitfall to Avoid:

Do not withhold magnesium sulfate simply because the patient is at 30+2 weeks rather than <30 weeks. While the strongest evidence exists for gestational ages <30 weeks, cerebral palsy rates remain elevated through 32-34 weeks, and the intervention has minimal maternal or fetal risks 8, 3. The potential neuroprotective benefit outweighs theoretical concerns at this gestational age.

Contraindications to Consider:

• Magnesium sulfate: Myasthenia gravis, renal failure (adjust dosing), hypocalcemia
• Corticosteroids: Active maternal infection is NOT a contraindication; pregestational diabetes at late preterm gestations (34-36 weeks) increases neonatal hypoglycemia risk but is not relevant at 30 weeks

Practical Implementation

1. Immediately upon decision that delivery is likely within 24-48 hours:

   • Administer first dose of betamethasone 12 mg IM
   • Initiate magnesium sulfate: 4 g IV loading dose over 20 minutes

2. Ongoing management:

   • Continue magnesium sulfate at 1 g/hour until delivery or 12 hours maximum
   • Administer second betamethasone dose 24 hours after the first
   • Monitor maternal reflexes, respirations, and fetal heart rate

3. If delivery does not occur within 48 hours:

   • Discontinue magnesium sulfate after 12 hours
   • Corticosteroid benefit persists for at least 7 days

This dual intervention approach addresses both immediate neonatal respiratory morbidity (via corticosteroids) and long-term neurodevelopmental outcomes (via magnesium sulfate), representing the current standard of care for anticipated preterm delivery at this gestational age 2, 4, 3, 1.